- Home
- SYRE vs GOF Comparison
SYRE vs GOF Comparison
Compare SYRE & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYRE | GOF |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SYRE | GOF |
|---|---|---|
| Price | $33.30 | $12.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $56.50 | N/A |
| AVG Volume (30 Days) | ★ 795.0K | 789.2K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.42% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.91 | $10.96 |
| 52 Week High | $35.31 | $16.76 |
Technical Indicators
Market Signals| Indicator | SYRE | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 52.53 |
| Support Level | $30.00 | $12.68 |
| Resistance Level | $34.21 | $13.07 |
| Average True Range (ATR) | 1.83 | 0.18 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 84.46 | 47.46 |
Price Performance
Historical ComparisonAbout SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.